Evidence map›Paper›PMID 28550494›Full record

ArticleThe European journal of health economics : HEPAC : health economics in prevention and care2018

Cost-effectiveness of combined serum anti-Helicobacter pylori IgG antibody and serum pepsinogen concentrations for screening for gastric cancer risk in Japan.

Shota Saito, Motoi Azumi, Yusuke Muneoka, Katsuhiko Nishino, Takashi Ishikawa, Yuichi Sato, Shuji Terai, Kouhei Akazawa

Abstract read
PubMed Publisher
In one paragraph

Article in The European journal of health economics : HEPAC : health economics in prevention and care, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
21citing papers in PubMed, 2 pooled it
3.0field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

21 citing papers in PubMed, 2 syntheses or guidelines pooled it, 32 citations in OpenAlex.

  1. Guideline
  2. Pooled it
  3. Trial
  4. Review
  5. Article
  6. Cost-Effectiveness of Empagliflozin in CKD with or without Albuminuria.Clinical journal of the American Society of Nephrology : CJASN · 2025
    Article
  7. Review
  8. Article
  9. Article
  10. Health economic evaluation on population-basedChinese journal of cancer research = Chung-kuo yen cheng yen chiu · 2023
    Article
  11. Article
  12. Cost-effectiveness of adding aEnvironmental and occupational health practice · 2023
    Article
  13. Article
  14. Article
  15. Risk factors for gastric cancer in Japan in the 2010s: a large, long-term observational study.Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association · 2022
    Observational
  16. Human gastric cancer risk screening: From rat pepsinogen studies to the ABC method.Proceedings of the Japan Academy. Series B, Physical and biological sciences · 2021
    Article
  17. Article
  18. Review
  19. Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 1 country.

Shota SaitoDepartment of Medical Informatics and Statistics, Niigata University Graduate School of Medical and Dental Sciences, Niigata, Japan. shota-saito@nuhw.ac.jp.
Motoi AzumiDepartment of Medical Informatics and Statistics, Niigata University Graduate School of Medical and Dental Sciences, Niigata, Japan.
Yusuke MuneokaDepartment of Medical Informatics and Statistics, Niigata University Graduate School of Medical and Dental Sciences, Niigata, Japan.
Katsuhiko NishinoDepartment of Medical Informatics and Statistics, Niigata University Graduate School of Medical and Dental Sciences, Niigata, Japan.
Takashi IshikawaDivision of Digestive and General Surgery, Niigata University Graduate School of Medical and Dental Sciences, Niigata, Japan.
Yuichi SatoDivision of Endoscopy, Niigata University Medical and Dental Hospital, Niigata, Japan.
Shuji TeraiDivision of Gastroenterology and Hepatology, Niigata University Graduate School of Medical and Dental Sciences, Niigata, Japan.
Kouhei AkazawaDepartment of Medical Informatics, Niigata University Medical and Dental Hospital, 1-754 Asahimachi, Chuo-ku, Niigata, 951-8520, Japan.
Niigata University · JPNiigata University Medical and Dental Hospital · JP

Funding

Grant-in-Aid for Research Activity Start-up and Challenging Research from the Niigata University of Health and Welfare, 2015 H27A01JSPS KAKENHI 16K08889
6 · The paper itself

Abstract

backgroundA combination of assays for the presence of serum anti-Helicobacter pylori IgG antibody (HPA) and serum pepsinogen (PG) concentrations can be used to screen for gastric cancer risk. In Japan, this "ABC method" is considered an effective means of stratifying gastric cancer risk. This study aimed to ascertain its cost-effectiveness for assessing gastric cancer risk.

methodsA Markov model was constructed to compare the cost-effectiveness of two strategies for gastric cancer-risk screening over a 30-year period: the ABC method, which uses a combination of assessing the presence of HPA and measuring serum PG concentrations and scheduling endoscopies accordingly, and annual endoscopic screening. Clinical and epidemiological data on variables in the model were obtained from published reports. Analyses were made from the perspective of the Japanese health care payer.

resultsAccording to base-case analysis, the ABC method cost less than annual endoscopic screening (64,489 vs. 64,074 USD) and saved more lives (18.16 vs. 18.30 quality-adjusted life years). One-way analyses confirmed the robustness of the cost-effectiveness results. The probability that the ABC method is cost-effective in Japanese individuals aged 50 years was 0.997.

conclusionsA combination of HPA and serum PG assays, plus scheduling endoscopy accordingly, is a cost-effective method of screening for gastric cancer risk in Japan.

Indexed as

Cost-Benefit AnalysisEarly Detection of CancerFemaleHelicobacter InfectionsHelicobacter pyloriHumansImmunoglobulin GJapanMaleMiddle AgedPepsinogen AStomach NeoplasmsImmunoglobulin GPepsinogen ACost-effectivenessGastric cancerHelicobacter pyloriMarkov modelScreening

Identifiers

PMID28550494
OpenAlexW2618845908

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.